Instil Bio, Inc. (TIL)

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.

This drugmaker's lead candidate could become a top-selling cancer therapy.

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024.

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.